Letter: treatment with subcutaneous CT‐P13 in Crohn’s disease patients with intravenous infliximab failure

Abstract

LINKED CONTENT This article is linked to Hanzel et al papers. To view these articles, visit https://doi.org/10.1111/apt.16609

Editorial: is there a role for monitoring intermediate anti‐TNF drug concentrations in IBD? Authors’ reply

“…It is also essential, as the editorialists noted, to analyse using drug‐tolerant assays, the early development of antibodies after subcutaneous treatment and particularly in patients already immunised after intravenous IFX. Switch to subcutaneous formulations has been associated with the reduction of anti‐IFX antibodies in patients already immunised and/or with infusion reactions 4 . Moreover, in case of loss of response where we are likely to optimise dosing, it may be necessary to measure and compare the pharmacokinetics of the 120 mg ew dose vs the 240 mg eow dose as shown with adalimumab 5 .…”

“…Switch to subcutaneous formulations has been associated with the reduction of anti-IFX antibodies in patients already immunised and/or with infusion reactions. 4 Moreover, in case of loss of response where we are likely to optimise dosing, it may be necessary to measure and compare the pharmacokinetics of the 120 mg ew dose vs the 240 mg eow dose as shown with adalimumab. 5 Finally, the contribution of rapid point of care (POC) tests could facilitate the TDM of these subcutaneous treatments, but it seems crucial to first establish and validate thresholds specific to these devices given that POCs tend to overestimate biotherapy trough levels as has been demonstrated with the intravenous agents.…”

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure

“…However, the number of patients included was very limited, and the main reason for switching was severe hypersensitivity reaction and/or immunogenicity rather than secondary LOR, such as in the current study. 19 SC infliximab differs in pharmacokinetics from IV infliximab. Administration via the IV route leads to early and rapid peak concentration followed by a steady decline to trough.…”

“…Only one case series has been reported, involving four CD patients who experienced failure with IV infliximab. 19 In this study, we assessed the clinical and biochemical responses after switching from IV to SC infliximab in UC patients who experienced a clinically and/or biochemically active disease during maintenance treatment of IV inflix-imab. Additionally, we investigated the pharmacokinetic profiles after SC switching in patients with active UC comparing them with those in patients with stable UC who underwent elective SC switching.…”

Opciones terapéuticas disponibles ante la falla al tratamiento anti-TNF en pacientes con Enfermedad Inflamatoria Intestinal

“…Así también, para aquellos pacientes que hayan presentado reacción a la infusión del fármaco endovenoso pudiesen ser candidatos a su uso subcutáneo por su menor riesgo de inmunogenicidad. Los beneficios que se han demostrado con esta vía de administración son la estabilidad de los niveles plasmáticos, menor inmunogenicidad,y mejor calidad de vida 61,62 .…”